Literature DB >> 18612994

Eye movement desensitization and reprocessing (EMDR) in the treatment of war veterans.

Steven M Silver1, Susan Rogers, Mark Russell.   

Abstract

Recent practice guidelines and meta-analyses have designated eye movement desensitization and reprocessing (EMDR) as a first-line treatment for trauma. Eye movement desensitization and reprocessing is an eight-phase therapeutic approach guided by an information-processing model that addresses the combat veteran's critical incidents, current triggers, and behaviors likely to prove useful in his or her future. Two case examples of combat veterans illustrate the ability of EMDR to achieve symptom reduction in a variety of clinical domains (e.g., anxiety, depression, anger, physical pain) simultaneously without requiring the patient to carry out homework assignments or discuss the details of the event. The treatment of phantom limb pain and other somatic presentations is also reviewed. The ability of EMDR to achieve positive effects without homework indicates that it can be effectively employed on consecutive days, making it especially useful during combat situations. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18612994     DOI: 10.1002/jclp.20510

Source DB:  PubMed          Journal:  J Clin Psychol        ISSN: 0021-9762


  3 in total

Review 1.  The grapes of war. Somatoform pain disorder and history of early war traumatization in older people.

Authors:  M Noll-Hussong; H Glaesmer; S Herberger; K Bernardy; C Schönfeldt-Lecuona; A Lukas; H Guendel; T Nikolaus
Journal:  Z Gerontol Geriatr       Date:  2012-07       Impact factor: 1.281

2.  Effective Treatment of Veterans With PTSD: Comparison Between Intensive Daily and Weekly EMDR Approaches.

Authors:  E C Hurley
Journal:  Front Psychol       Date:  2018-08-24

3.  Quality of life in elderly Portuguese war veterans with post-traumatic stress symptoms.

Authors:  M Graça Pereira; José C Machado; Marta Pereira; Cristiana Lopes; Susana Pedras
Journal:  Patient Relat Outcome Meas       Date:  2019-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.